C ongestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like peptide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function.
Introduction
The most common reasons for congestive heart failure (CHF) are coronary artery disease and hypertension. However, abnormal myocardial metabolism may also play a role. 1, 2 Diabetes mellitus is an independent predictor of CHF, and patients with CHF are significantly more prone to develop diabetes with time. 3 Moreover, diastolic dysfunction, even without overt clinical signs of CHF, is common in the diabetic population. 4, 5 This has been attributed, at least in part, to metabolic perturbations characterised by increased free fatty acid utilisation and decreased glucose oxidation, which may ORIGINAL ARTICLE Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure A significant reduction in fasting blood glucose was observed on day 2 (p=0.006) influence myocardial function considerably. [6] [7] [8] [9] [10] Similar disturbances may compromise the myocardial function even in the non-diabetic CHF patient. Stimulation of glucagon-like peptide-1 (GLP-1) receptors causes a glucose-dependent secretion of insulin. This might exert metabolic control without a demand for repeated blood glucose control and with little risk of symptomatic hypoglycaemia. Recombinant GLP-1 represents a novel insulinotropic agent with major therapeutic potential for the treatment of type 2 diabetes mellitus. [11] [12] [13] [14] GLP-1 has not previously been administered to diabetic patients with CHF: it may, however, have the potential to improve myocardial metabolism, causing functional improvement, with a minimal risk of hypoglycaemia. GLP-1 was shown to improve cardiovascular function in a canine model of pacing-induced heart failure. 15 
Aims
The primary objective of this study was to assess the feasibility and safety of recombinant GLP-1 in heart failure patients, together with the effect on left ventricular systolic and diastolic function as measured by myocardial tissue Doppler imaging (TDI) at rest and in response to sub-maximal exercise.
Methods
The study was conducted as a pilot, open observation on the effects of recombinant GLP-1 (rGLP-1) in six hospitalised male patients with stable type 2 diabetes and ischaemic congestive heart failure. Recombinant GLP-1 was given as a subcutaneous infusion over a period of three days. The patients were in stable heart failure, New York Heart Association (NYHA) class II-III, with a left ventricular (LV) ejection fraction <40%.
Following initial echocardiographic examination and blood sampling, rGLP-1 was administered by a subcutaneous infusion of 4 pmol/kg/min, or in the case of nausea during the infusion 3 pmol/kg/min, for 72 hours. A second echocardiographic examination and blood sampling were conducted at the end of the infusion, and then the rGLP-1 was discontinued. The examinations before and during the infusion included physical examination, standard twodimensional echocardiography at rest and during submaximal supine exercise (approximately 50% of the predetermined exercise capacity), and myocardial TDI.
The ethics committee at the Karolinska Institute and the Swedish Medical Product Agency approved the study protocol. All patients gave their written informed consent to participation.
Results
All patients completed the study protocol. Their demographic characteristics are outlined in table 1. Due to nausea, the infusion rate was reduced by 25% (to 3 pmol/kg/min) during study days 2 and 3 in two participants. Five of the six patients spontaneously reported symptomatic subjective improvement on the second and third day of GLP-1 infusion. Figure 1 shows that the average fasting blood glucose decreased significantly on day two but increased somewhat after that. Table 2 presents the plasma concentrations of insulin, glucagon and C-peptide in the six patients, plus the mean values. Free fatty acids were unchanged in two of the six patients and decreased somewhat in the remaining four. Figure 2 shows GLP-1 values during the study period. A trend towards a reduction of resting heart rate was observed at days 2 and 3, but was minimal at day 4. Similarly, there was a slight trend towards decreasing systolic blood pressure and increasing diastolic blood pressure. The mean ejection fraction was 30±5%. The average left ventricular end-diastolic diameter before GLP-1 was 58±6 mm. The rate pressure product became somewhat lower during the study period, both at rest and stress (table 3) .
The results of tissue Doppler imaging are reported in table 4. As can be seen, there was a (statistically insignificant) trend towards improved global systolic and diastolic function at rest and during exercise following the GLP-1 infusion. The inter-observer variations in analysing the myocardial tissue Doppler imaging was 20%.
Conclusion
In this pilot investigation, GLP-1 improved metabolic control and caused a trend towards improvement of parameters expressing LV function in type 2 diabetic patients with stable heart failure. The improvement was small and, as always, the outcome of a pilot investigation must be interpreted with great caution. The number of study patients permitted for this pilot study was too small for standard statistical calculations and the confidence intervals are wide. Moreover, the study did not have a control group randomised to placebo.
An attempt at administering GLP-1 has, to our knowledge, not been made previously in heart failure patients. This was also the reason why we conducted this first observational investigation as an open study design. As precautionary measures, we used a restricted dose of GLP-1 and adjusted orally-taken antidiabetic drugs when the blood glucose became low. None of the patients, however, had any symptoms or signs of hypoglycaemia. The reduction of the medications was, therefore, a measure of our extreme caution. The infusion rate of GLP-1 was decreased in two patients who experienced nausea, and this disappeared fol-ORIGINAL ARTICLE lowing dose adjustment. Nausea is a known side effect of GLP-1, apparently related to delayed gastric emptying. 13, 14 Together with adjustments of the oral antidiabetic treatment, this probably influenced the degree of metabolic control achieved. A more invasive method of measuring cardiac output or central blood pressures may be needed in order to evaluate marginal improvements of myocardial function; TDI imaging was perhaps too insensitive.
In conclusion, the outcome of this pilot study indicates that GLP-1 may be a possible treatment for heart failure patients with type 2 diabetes. The study also demonstrates the safety and feasibility of this treatment. This forms the basis for further trials to investigate dosages of GLP-1 over a longer observation time and with a greater number of patients. Such studies would be of great interest in finding pharmacological tools to improve myocardial metabolism, as a novel approach in CHF management.
